#None #Los Angeles #Partillion Bioscience #Nanovial Technology #Cell-Cell-seq

Partillion Bioscience Secures $2.1 Million NIH SBIR Grant

On September 9, 2026, Partillion Bioscience made headlines with the announcement of a significant two-year, $2.1 million grant awarded by the National Institutes of Health (NIH). This funding, part of the NIH's Small Business Innovation Research (SBIR) program, aims to accelerate the advancements of the company's innovative Cell-Cell-seq workflows, a technology that plays a pivotal role in single-cell analysis.

Addressing the Gap in Single Cell Analysis

The traditional approach in single-cell sequencing typically involves analyzing cells in isolation. This presents a considerable limitation for researchers, as it restricts their ability to thoroughly explore the critical interactions that occur between cells and their effects on disease processes as well as therapeutic responses. The recent NIH grant, awarded through the Direct-to-Phase II mechanism, is poised to significantly enhance Partillion's Cell-Cell-seq technology, grounded in the company's proprietary Nanovial technology.

With 17 patents associated with its innovative technology, Partillion's Cell-Cell-seq involves profiling defined pairs of cells, thus capturing essential functional outputs including secretion, activation, and cytotoxic effects. Such capabilities are set to elevate the datasets produced through this technology, allowing for the analysis of interactions among up to one million cell pairs and ensuring compatibility with additional sequencing platforms.

Driving Forward In Research and Commercial Opportunities

Joseph de Rutte, the Co-Founder and CEO of Partillion Bioscience, expressed enthusiasm about the new funding, noting its importance in advancing the scientific credibility of Cell-Cell-seq. The financial support will enable the company to continue conducting groundbreaking research, allowing for further exploration of its unique technological advantages while simultaneously focusing on expanding its customer base and commercial endeavors.

The latest grant marks Partillion's tenth SBIR award, raising the company's total non-dilutive federal funding to over $8 million. This figure is remarkable, especially considering that it aligns closely with the company's private investments so far, all without exchanging equity. This balance reflects the strong demand and interest in Partillion's capabilities within both the academic and commercial sectors.

In addition to the grant, Partillion has recently formed a distribution partnership with Sony Biotechnology and is collaborating on an influential research initiative alongside esteemed institutions such as UCLA, USC, and Caltech, with support from the Chan Zuckerberg Initiative. Such collaborations indicate not only industry momentum but also the growing recognition of the essential role that Cell-Cell-seq technology plays in advancing current scientific understanding.

Future Prospects and Market Expansion

The trajectory of Partillion's Nanovial platform is becoming increasingly promising. Experts such as Eric Moessinger from NanoDimension, Inc., believe that by enhancing compatibility with leading single-cell sequencing platforms and creating analysis software, the company is ideally positioned for commercial growth. As Partillion works to expand accessibility to its innovative technology, the opportunity to generate large-scale datasets that highlight cell interactions becomes more attainable.

As Partillion Bioscience continues to empower researchers with sophisticated analytical tools for cell interaction studies, the implications for drug development and personalized medicine may prove substantial. By enabling deeper insights into cellular communication and its impact on health, Partillion is adeptly positioning itself at the forefront of the biopharmaceutical landscape.

In summary, the emerging capabilities of Partillion’s technology supported by the recent NIH grant not only hint at improvements in research methodologies but also pave the way for significant advancements within therapeutic fields. As part of its commitment to bringing valuable innovations to the market, Partillion showcases the potential to catalyze transformative changes in how scientists approach complex biological systems.